Quick Answer
Protalix BioTherapeutics, Inc. reported Operating Income of -$5.50 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$5.50M | -240.4% |
| 2024 | $3.92M | -62.6% |
| 2023 | $10.46M | +180.4% |
| 2022 | -$13.01M | +36.4% |
| 2021 | -$20.46M | -855.1% |
| 2020 | $2.71M | +125.3% |
| 2019 | -$10.72M | +44.5% |
| 2018 | -$19.31M | +44.1% |
| 2017 | -$34.52M | -4.1% |
| 2016 | -$33.16M | -40.1% |
| 2015 | -$23.67M | +17.1% |
| 2014 | -$28.56M | +16.2% |
| 2013 | -$34.06M | -179.8% |
| 2012 | -$12.17M | +66.7% |
| 2011 | -$36.53M | -21.9% |
| 2010 | -$29.97M | +6.3% |
| 2009 | -$31.97M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.13M | -46.6% | +81.8% |
| June 30, 2025 | $1.17M | +148.3% | +128.3% |
| March 31, 2025 | -$4.14M | +14.6% | -203.9% |
| September 30, 2024 | $3.99M | +311.5% | +264.4% |
| June 30, 2024 | -$2.43M | -111.9% | +50.0% |
| March 31, 2024 | -$4.86M | -97.5% | -157.3% |
| September 30, 2023 | -$1.89M | +39.6% | -109.2% |
| June 30, 2023 | $20.42M | +469.7% | +930.5% |
- Protalix BioTherapeutics, Inc. showed a decrease of -240.4% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Protalix BioTherapeutics, Inc.’s operating income has grown by 82.8% (from -$31.97 million to -$5.50 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: